Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 7/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299336 | 0.89 | NAMPT (0.33) | NAMPTMGLLALKLMNAHTR2B | |
| SCHEMBL12386298 | 0.89 | TNKS (0.38) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL12386297 | 0.86 | TNKS (0.39) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL1751913 | 0.85 | RIPK1 (0.39) | NAMPTMGLLALKLMNAHTR2B | |
| SCHEMBL2301303 | 0.84 | NAMPT (0.41) | NAMPTTNKSTNKS2MGLL | |
| SCHEMBL2302392 | 0.84 | NAMPT (0.41) | NAMPTTNKSTNKS2MGLL | |
| SCHEMBL2301150 | 0.82 | NAMPT (0.41) | NAMPTTNKSTNKS2MGLLALK | |
| SCHEMBL2299298 | 0.82 | NAMPT (0.41) | NAMPTTNKSTNKS2MGLLALK | |
| SCHEMBL2296894 | 0.82 | NAMPT (0.41) | NAMPTTNKSTNKS2MGLLALK | |
| SCHEMBL2299295 | 0.80 | NAMPT (0.39) | NAMPTTNKSTNKS2MGLLALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2021337-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | NAMPT 1816/4885TNKS 1999/4885TNKS2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.